EryDel hires Maxer to implement its 2021 Clinical Trial Disclosure program
We are pleased to announce that the EryDel S.p.A. has entrusted Maxer Consulting to implement the Clinical Trial Disclosure program for 2021.
Maxer will carry out the necessary activities to ensure EryDel’s compliance with the regulations in force in the European Union (EU Reg. 536/2014) and the United States (FDAAA 801, Final Rule) and the transparency of clinical studies’ results.
Comments are closed.